Efficacy Evaluation of Dai Dai Flower on Body Weight
- Conditions
- Gastroenterology
- Registration Number
- NCT04692792
- Lead Sponsor
- TCI Co., Ltd.
- Brief Summary
To assess the Dai Dai flower extract on body weight control
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
- Healthy male or female aged between 20 and 60 years old
- Body mass index (BMI) ≥ 24 (kg/m^2) or body fat mass ≥ 25%
- Pregnant or breastfeeding woman
- Implementation in weight loss programs, consumption drugs or supplements for weight control before 3 months of this study
- Participate weight control or fat loss human studies before 3 months of this study
- History of cardiovascular disease, liver disease, kidney disease, endocrine disease, or other major organic diseases (according to subjects reporting).
- Person who has received major surgery or bariatric surgery (according to medical history).
- Person who has received constant drug use.
- People with mental illness
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method The change of body weight Change from Baseline body weight at 8 weeks The body weight (kg) was assessed by InBody.
The change of BMI Change from Baseline BMI at 8 weeks The BMI was assessed by InBody.
- Secondary Outcome Measures
Name Time Method The change of IFN-γ Change from Baseline IFN-γ at 8 weeks Venous blood was sampled to measure concentrations of IFN-γ
The change of IL-2 Change from Baseline IL-2 at 8 weeks Venous blood was sampled to measure concentrations of IL-2
The change of IL-1beta Change from Baseline IL-1beta at 8 weeks Venous blood was sampled to measure concentrations of IL-1beta
The change of leptin Change from Baseline leptin at 8 weeks Venous blood was sampled to measure concentrations of leptin
The change of body fat mass Change from Baseline body fat mass at 8 weeks The body fat mass (kg) was assessed by InBody.
The change of visceral fat mass Change from Baseline visceral fat mass at 8 weeks The visceral fat mass (kg) was assessed by InBody.
The change of waist-hip ratio Change from Baseline waist-hip ratio at 8 weeks The waist-hip ratio was assessed by measuring tape.
The change of basal metabolic rate Change from Baseline basal metabolic rate at 8 weeks The basal metabolic rate was assessed by InBody.
The change of AST Change from Baseline AST at 8 weeks Venous blood was sampled to measure concentrations of aspartate transaminase (AST)
The change of ALT Change from Baseline ALT at 8 weeks Venous blood was sampled to measure concentrations of alanine aminotransferase (ALT)
The change of Creatinine Change from Baseline creatinine at 8 weeks Venous blood was sampled to measure concentrations of creatinine
The change of BUN Change from Baseline BUN at 8 weeks Venous blood was sampled to measure concentrations of blood urea nitrogen (BUN)
The change of fasting glycemia Change from Baseline fasting glycemia at 8 weeks Venous blood was sampled to measure concentrations of fasting glycemia
The change of total cholesterol Change from Baseline total cholesterol at 8 weeks Venous blood was sampled to measure concentrations of total cholesterol
The change of triglyceride Change from Baseline triglyceride at 8 weeks Venous blood was sampled to measure concentrations of triglyceride
The change of HDL-cholesterol Change from Baseline HDL-cholesterol at 8 weeks Venous blood was sampled to measure concentrations of HDL-cholesterol
The change of LDL-cholesterol Change from Baseline LDL-cholesterol at 8 weeks Venous blood was sampled to measure concentrations of LDL-cholesterol
The change of insulin Change from Baseline insulin at 8 weeks Venous blood was sampled to measure concentrations of insulin
The change of adiponectin Change from Baseline adiponectin at 8 weeks Venous blood was sampled to measure concentrations of adiponectin
Trial Locations
- Locations (1)
China Medical University
🇨🇳Taichung, Taiwan
China Medical University🇨🇳Taichung, Taiwan